S&P 500   4,290.91 (+0.20%)
DOW   33,746.21 (-0.05%)
QQQ   354.47 (-0.05%)
AAPL   182.82 (+1.03%)
MSFT   334.23 (-0.35%)
META   270.82 (-0.66%)
GOOGL   124.36 (-0.25%)
AMZN   124.33 (+0.06%)
TSLA   217.40 (+1.60%)
NVDA   388.65 (-1.17%)
NIO   7.64 (+1.06%)
BABA   83.93 (-0.40%)
AMD   116.21 (-1.40%)
T   15.33 (+0.79%)
F   12.69 (+2.42%)
MU   69.25 (+0.12%)
CGC   0.84 (+1.68%)
GE   105.50 (-0.28%)
DIS   91.21 (+0.48%)
AMC   4.61 (+1.32%)
PFE   38.33 (-0.08%)
PYPL   63.97 (+0.02%)
NFLX   401.88 (+0.35%)
S&P 500   4,290.91 (+0.20%)
DOW   33,746.21 (-0.05%)
QQQ   354.47 (-0.05%)
AAPL   182.82 (+1.03%)
MSFT   334.23 (-0.35%)
META   270.82 (-0.66%)
GOOGL   124.36 (-0.25%)
AMZN   124.33 (+0.06%)
TSLA   217.40 (+1.60%)
NVDA   388.65 (-1.17%)
NIO   7.64 (+1.06%)
BABA   83.93 (-0.40%)
AMD   116.21 (-1.40%)
T   15.33 (+0.79%)
F   12.69 (+2.42%)
MU   69.25 (+0.12%)
CGC   0.84 (+1.68%)
GE   105.50 (-0.28%)
DIS   91.21 (+0.48%)
AMC   4.61 (+1.32%)
PFE   38.33 (-0.08%)
PYPL   63.97 (+0.02%)
NFLX   401.88 (+0.35%)
S&P 500   4,290.91 (+0.20%)
DOW   33,746.21 (-0.05%)
QQQ   354.47 (-0.05%)
AAPL   182.82 (+1.03%)
MSFT   334.23 (-0.35%)
META   270.82 (-0.66%)
GOOGL   124.36 (-0.25%)
AMZN   124.33 (+0.06%)
TSLA   217.40 (+1.60%)
NVDA   388.65 (-1.17%)
NIO   7.64 (+1.06%)
BABA   83.93 (-0.40%)
AMD   116.21 (-1.40%)
T   15.33 (+0.79%)
F   12.69 (+2.42%)
MU   69.25 (+0.12%)
CGC   0.84 (+1.68%)
GE   105.50 (-0.28%)
DIS   91.21 (+0.48%)
AMC   4.61 (+1.32%)
PFE   38.33 (-0.08%)
PYPL   63.97 (+0.02%)
NFLX   401.88 (+0.35%)
S&P 500   4,290.91 (+0.20%)
DOW   33,746.21 (-0.05%)
QQQ   354.47 (-0.05%)
AAPL   182.82 (+1.03%)
MSFT   334.23 (-0.35%)
META   270.82 (-0.66%)
GOOGL   124.36 (-0.25%)
AMZN   124.33 (+0.06%)
TSLA   217.40 (+1.60%)
NVDA   388.65 (-1.17%)
NIO   7.64 (+1.06%)
BABA   83.93 (-0.40%)
AMD   116.21 (-1.40%)
T   15.33 (+0.79%)
F   12.69 (+2.42%)
MU   69.25 (+0.12%)
CGC   0.84 (+1.68%)
GE   105.50 (-0.28%)
DIS   91.21 (+0.48%)
AMC   4.61 (+1.32%)
PFE   38.33 (-0.08%)
PYPL   63.97 (+0.02%)
NFLX   401.88 (+0.35%)
NASDAQ:SNDX

Syndax Pharmaceuticals (SNDX) Stock Forecast, Price & News

$20.47
+0.30 (+1.49%)
(As of 06/2/2023 06:55 PM ET)
Compare
Today's Range
$19.99
$20.56
50-Day Range
$19.35
$22.26
52-Week Range
$14.69
$29.86
Volume
1.13 million shs
Average Volume
849,037 shs
Market Capitalization
$1.41 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$33.86

Syndax Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
65.4% Upside
$33.86 Price Target
Short Interest
Bearish
9.29% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-1.12
Upright™ Environmental Score
News Sentiment
0.73mentions of Syndax Pharmaceuticals in the last 14 days
Based on 6 Articles This Week
Insider Trading
Selling Shares
$3.35 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($2.98) to ($2.89) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.44 out of 5 stars

Medical Sector

146th out of 980 stocks

Pharmaceutical Preparations Industry

64th out of 485 stocks


SNDX stock logo

About Syndax Pharmaceuticals (NASDAQ:SNDX) Stock

Syndax Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the development of cancer therapies. Its product candidates include SNDX-5613 and SNDX-6352. The company was founded by Richard A. Heyman, Eckard Weber, Peter Ordentlich, Ronald M. Evans and Michael Downes on October 11, 2005 and is headquartered in Waltham, MA.

Receive SNDX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Syndax Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SNDX Stock News Headlines

AI industry Is Exploding! New Breakthrough Expected this Summer
Bill Gates says the AI Era has begun. Every tech company is looking to integrate artificial intelligence. A young company holds the secret to the next biggest AI advancement.
Syndax Pharmaceuticals (SNDX) Receives a Buy from Goldman Sachs
AI industry Is Exploding! New Breakthrough Expected this Summer
Bill Gates says the AI Era has begun. Every tech company is looking to integrate artificial intelligence. A young company holds the secret to the next biggest AI advancement.
Syndax Pharmaceuticals (NASDAQ:SNDX) PT Lowered to $31.00
Q1 2023 Syndax Pharmaceuticals Inc Earnings Call
Goldman Sachs Remains a Buy on Syndax Pharmaceuticals (SNDX)
Syndax Pharmaceuticals (NASDAQ:SNDX) Trading Down 3.6%
See More Headlines

SNDX Price History

SNDX Company Calendar

Last Earnings
5/08/2023
Today
6/05/2023
Next Earnings (Estimated)
8/14/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SNDX
Employees
59
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$33.86
High Stock Price Forecast
$37.00
Low Stock Price Forecast
$31.00
Forecasted Upside/Downside
+65.4%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
6 Analysts

Profitability

Net Income
$-149,340,000.00
Pretax Margin
-11.02%

Debt

Sales & Book Value

Annual Sales
$139.71 million
Book Value
$7.76 per share

Miscellaneous

Free Float
65,586,000
Market Cap
$1.41 billion
Optionable
Optionable
Beta
1.13

Key Executives

  • Michael A. MetzgerMichael A. Metzger
    Chief Executive Officer & Director
  • Neil Gallagher
    President, Head-Research & Development
  • Keith Alan Goldan
    Treasurer, Chief Financial & Accounting Officer
  • Peter OrdentlichPeter Ordentlich
    Chief Scientific Officer
  • Briggs W. MorrisonBriggs W. Morrison
    Director













SNDX Stock - Frequently Asked Questions

Should I buy or sell Syndax Pharmaceuticals stock right now?

6 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Syndax Pharmaceuticals in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SNDX shares.
View SNDX analyst ratings
or view top-rated stocks.

What is Syndax Pharmaceuticals' stock price forecast for 2023?

6 Wall Street analysts have issued twelve-month price targets for Syndax Pharmaceuticals' stock. Their SNDX share price forecasts range from $31.00 to $37.00. On average, they anticipate the company's share price to reach $33.86 in the next twelve months. This suggests a possible upside of 65.4% from the stock's current price.
View analysts price targets for SNDX
or view top-rated stocks among Wall Street analysts.

How have SNDX shares performed in 2023?

Syndax Pharmaceuticals' stock was trading at $25.45 at the beginning of the year. Since then, SNDX shares have decreased by 19.6% and is now trading at $20.47.
View the best growth stocks for 2023 here
.

When is Syndax Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our SNDX earnings forecast
.

How were Syndax Pharmaceuticals' earnings last quarter?

Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) issued its earnings results on Monday, May, 8th. The company reported ($0.59) EPS for the quarter, beating the consensus estimate of ($0.61) by $0.02.

What other stocks do shareholders of Syndax Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Syndax Pharmaceuticals investors own include OPKO Health (OPK), Exelixis (EXEL), Verastem (VSTM), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Idera Pharmaceuticals (IDRA), TherapeuticsMD (TXMD) and Micron Technology (MU).

When did Syndax Pharmaceuticals IPO?

(SNDX) raised $66 million in an initial public offering (IPO) on Thursday, March 3rd 2016. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Morgan Stanley and Citigroup served as the underwriters for the IPO and JMP Securities and Oppenheimer & Co. were co-managers.

What is Syndax Pharmaceuticals' stock symbol?

Syndax Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNDX."

Who are Syndax Pharmaceuticals' major shareholders?

Syndax Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Wellington Management Group LLP (10.22%), BlackRock Inc. (7.15%), State Street Corp (5.62%), Jennison Associates LLC (3.53%), BVF Inc. IL (3.11%) and Dimensional Fund Advisors LP (1.93%). Insiders that own company stock include Alexander Nolte, Briggs Morrison, Dennis Podlesak, Fabrice Egros, Keith Katkin, Michael A Metzger, Michael L Meyers, Peter Ordentlich and Pierre Legault.
View institutional ownership trends
.

How do I buy shares of Syndax Pharmaceuticals?

Shares of SNDX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Syndax Pharmaceuticals' stock price today?

One share of SNDX stock can currently be purchased for approximately $20.47.

How much money does Syndax Pharmaceuticals make?

Syndax Pharmaceuticals (NASDAQ:SNDX) has a market capitalization of $1.41 billion and generates $139.71 million in revenue each year. The company earns $-149,340,000.00 in net income (profit) each year or ($2.41) on an earnings per share basis.

How can I contact Syndax Pharmaceuticals?

Syndax Pharmaceuticals' mailing address is 35 GATEHOUSE DRIVE BUILDING D FLOOR 3, WALTHAM MA, 02451. The official website for the company is www.syndax.com. The company can be reached via phone at (781) 419-1400, via email at ir@syndax.com, or via fax at 781-419-1420.

This page (NASDAQ:SNDX) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -